UPDATE 1-Barr seeks OK of generic form of Sanofi's Eloxatin

Wed Jan 9, 2008 11:50am EST

Related Topics

(Recasts, adds details, dateline)

NEW YORK Jan 9 (Reuters) - Barr Pharmaceuticals Inc BRL.N said on Wednesday it has asked U.S. regulators to approve its generic form of French drugmaker Sanofi-Aventis' (SASY.PA) blockbuster Eloxatin treatment for colon cancer.

Barr said Sanofi-Aventis and its partner, privately held Swiss drugmaker Debiopharm S.A., in turn, last week filed suit in New Jersey federal court to prevent Barr from taking its generic to market.

Eloxatin, which is given by injection, is used to treat stage III colon cancer patients who have undergone complete removal of their primary tumor, and to also treat advanced cancer of the colon or rectum.

It had U.S. sales of about $1.1 billion during the 12-months ended October 2007, Barr said. (Reporting by Ransdell Pierson, additional reporting by Supantha Mukherjee in Bangalore; Editing by Tim Dobbyn)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

California state worker Albert Jagow (L) goes over his retirement options with Calpers Retirement Program Specialist JeanAnn Kirkpatrick at the Calpers regional office in Sacramento, California October 21, 2009. Calpers, the largest U.S. public pension fund, manages retirement benefits for more than 1.6 million people, with assets comparable in value to the entire GDP of Israel. The Calpers investment portfolio had a historic drop in value, going from a peak of $250 billion in the fall of 2007 to $167 billion in March 2009, a loss of about a third during that period. It is now around $200 billion. REUTERS/Max Whittaker   (UNITED STATES) - RTXPWOZ

How to get out of debt

Financial adviser Eric Brotman offers strategies for cutting debt from student loans and elder care -- and how to avoid money woes in the first place.  Video